<DOC>
	<DOCNO>NCT01249430</DOCNO>
	<brief_summary>This phase I clinical trial study side effect best dose azacitidine give together mitoxantrone , etoposide phosphate , cytarabine treat patient relapsed refractory acute myeloid leukemia . Azacitidine may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , mitoxantrone , etoposide phosphate , cytarabine , work different way stop growth cancer cell , either kill cell stop dividing . Azacitidine may help mitoxantrone , etoposide phosphate , cytarabine work well make cancer cell sensitive drug .</brief_summary>
	<brief_title>Azacitidine Combination With Mitoxantrone , Etoposide Phosphate , Cytarabine Treating Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum-tolerated dose azacitidine combine salvage chemotherapy comprise mitoxantrone hydrochloride , etoposide phosphate , cytarabine ( MEC ) patient relapse refractory acute myeloid leukemia ( AML ) . SECONDARY OBJECTIVES : I . To define qualitative quantitative toxicity azacitidine combination MEC regard organ specificity , time course , predictability , reversibility . II . To document rate complete remission ( CR ) CR incomplete blood count recovery ( CRi ) patient treat combination agent . III . To determine overall survival , relapse-free survival , event-free survival patient treated combination agent . IV . To evaluate pharmacokinetics azacitidine give combination MEC patient enrol study . ( Exploratory ) V. To measure R2 regulation , include change R2 target , AraCTP , dNTP/NTP pool , azacitidine give combination MEC correlate pharmacodynamic endpoint clinical response . ( Exploratory ) VI . To evaluate hypomethylation , include DMNT1 expression , Sp1 expression , global DNA methylation , gene expression profiling , microRNA expression profiling , azacitidine give combination MEC correlate pharmacodynamic change clinical response . ( Exploratory ) OUTLINE : This dose-escalation study azacitidine . Patients receive azacitidine IV 30 minute day 1-8 mitoxantrone hydrochloride IV 10 minute , etoposide phosphate IV 30-60 minute , cytarabine IV 6 hour day 3-8 absence disease progression unacceptable toxicity . Treatment may repeat every 8 day 1 additional course . Blood bone marrow sample collect baseline periodically study pharmacokinetic pharmacodynamic study . After completion study therapy , patient follow 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Histologically cytologically confirm acute myeloid leukemia Relapsed refractory disease accord 2008 WHO classification Must fail ≥ 1 course induction chemotherapy relapse achieve complete remission induction therapy No active central nervous system disease granulocytic sarcoma sole site disease ECOG performance status ( PS ) 02 ( Karnofsky PS 60100 % ) Life expectancy &gt; 6 month comorbid condition Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Creatinine ≤ 1.5 mg/dL LVEF ≥ 40 % Not pregnant nursing Negative pregnancy test No history allergic reaction attribute compound similar chemical biologic composition azacitidine , mannitol , agent use study No uncontrolled intercurrent illness include , limited , follow : Symptomatic congestive heart failure Unstable angina pectoris Serious cardiac arrhythmia Psychiatric illness and/or social situation would limit compliance study requirement None follow : Myocardial infarction within past 6 month NYHA class III IV heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmia Electrocardiographic evidence acute ischemia active conduction system abnormalities Patients active infection allow provided infection control No concurrent anticancer agent therapy , include chemotherapy , radiotherapy ( include palliative ) , biologic response modifier Prior autologous allogeneic stem cell transplantation allow Recovered nonhematologic toxicity &lt; grade 2 More 2 week since prior chemotherapy radiotherapy ( 6 week nitrosoureas mitomycin C ) More 14 day since prior concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>